Exploring Nemvaleukin Alfa Monotherapy & in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Time: 11:30 am
day: Conference Day Two


  • Outlining nemvaleukin as a novel engineered cytokine
  • Revealing the design to selectively bind to intermediate-affinity interleukin-2 receptor (IL-2R) for preferential activation and expansion of tumor-killing CD8+ T cells and natural
  • killer (NK) cells, with minimal expansion of regulatory T cells (Tregs)
  • Discussing the potential to reduce native IL-2’s toxicities, thus allowing greater tolerability and efficacy than other IL-2 molecules have shown in the past